[1] |
Gibbs S. Skin disease and socioeconomic conditions in rural Africa: Tanzania[J]. Int J Dermatol, 1996,35(9):633⁃639.
|
[2] |
Danielsen K, Olsen AO, Wilsgaard T, et al. Is the prevalence of psoriasis increasing? A 30⁃year follow⁃up of a population⁃based cohort[J]. Br J Dermatol, 2013,168(6):1303⁃1310. doi: 10.1111/ bjd.12230.
|
[3] |
Shao CG, Zhang GW, Wang GC. Distribution of psoriasis in China: a nationwide screening[J]. Proc Chin Acad Med Sci Peking Union Med Coll, 1987,2(2):59⁃65.
|
[4] |
丁晓岚, 王婷琳, 沈佚葳, 等. 中国六省市银屑病流行病学调查[J]. 中国皮肤性病学杂志, 2010,24(7):598⁃601.
|
[5] |
中华医学会皮肤性病学分会银屑病学组. 中国银屑病治疗指南(2008版)[J]. 中华皮肤科杂志, 2009,42(3):213⁃214. doi: 10.3760/cma.j.issn.0412⁃4030.2009.03.030.
|
[6] |
中华医学会皮肤性病学分会银屑病学组. 中国银屑病治疗专家共识(2014版)[J]. 中华皮肤科杂志,2014, 47(3):213⁃215. doi: 10.3760/cma.j.issn.0412⁃4030.2014.03.017.
|
[7] |
Wong T, Hsu L, Liao W. Phototherapy in psoriasis: a review of mechanisms of action[J]. J Cutan Med Surg, 2013,17(1):6⁃12. doi: 10.2310/7750.2012.11124.
|
[8] |
Koo J, Bandow G, Feldman SR, et al. The art and practice of UVB phototherapy for the treatment of psorasis//Weinstein GD, Gottlieb AB. Therapy of moderate⁃to⁃severe psorasis[M]. New York: Marcel Dekker, 2003:53⁃90.
|
[9] |
Bianchi B, Campolmi P, Mavilia L, et al. Monochromatic excimer light (308 nm): an immunohistochemical study of cutaneous T cells and apoptosis⁃related molecules in psoriasis[J]. J Eur Acad Dermatol Venereol, 2003,17(4):408⁃413.
|
[10] |
Feldman SR, Mellen BG, Housman TS, et al. Efficacy of the 308⁃nm excimer laser for treatment of psoriasis: results of a multicenter study[J]. J Am Acad Dermatol, 2002,46(6):900⁃906.
|
[11] |
Bagel J. Adalimumab plus narrowband ultraviolet B light photo⁃therapy for the treatment of moderate to severe psoriasis[J]. J Drugs Dermatol, 2011,10(4):366⁃371.
|
[12] |
Vidal D, Salleras M, Romaní J, et al. Adherence of self⁃administered subcutaneous methotrexate in patients with chronic plaque⁃type psoriasis[J]. J Eur Acad Dermatol Venereol, 2016,30(11):e131⁃e132. doi: 10.1111/jdv.13409.
|
[13] |
Shea B, Swinden MV, Ghogomu ET, et al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis[J]. J Rheumatol, 2014,41(6):1049⁃1060. doi: 10.3899/jrheum.130738.
|
[14] |
Cline A, Jorizzo JL. Does daily folic acid supplementation reduce methotrexate efficacy?[J/OL]. Dermatol Online J, 2017,23(11):6. pii: 13030/qt4hf5v2vk.
|
[15] |
Prey S, Paul C. Effect of folic or folinic acid supplementation on methotrexate⁃associated safety and efficacy in inflammatory disease: a systematic review[J]. Br J Dermatol, 2009,160(3):622⁃628. doi: 10.1111/j.1365⁃2133.2008.08876.x.
|
[16] |
Ortiz Z, Shea B, Suarez⁃Almazor ME, et al. The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis. A metaanalysis of randomized controlled trials[J]. J Rheumatol, 1998,25(1):36⁃43.
|
[17] |
Duhra P. Treatment of gastrointestinal symptoms associated with methotrexate therapy for psoriasis[J]. J Am Acad Dermatol, 1993,28(3):466⁃469.
|
[18] |
Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents[J]. J Am Acad Dermatol, 2009,61(3):451⁃485. doi: 10.1016/j.jaad.2009.03.027.
|
[19] |
Faerber L, Braeutigam M, Weidinger G, et al. Cyclosporine in severe psoriasis. Results of a meta⁃analysis in 579 patients[J]. Am J Clin Dermatol, 2001,2(1):41⁃47. doi: 10.2165/00128071⁃200102010⁃00007.
|
[20] |
Ho VC, Griffiths CE, Albrecht G, et al. Intermittent short courses of cyclosporin (Neoral(R)) for psoriasis unresponsive to topical therapy: a 1⁃year multicentre, randomized study. The PISCES Study Group[J]. Br J Dermatol, 1999,141(2):283⁃291.
|
[21] |
Ho VC, Griffiths CE, Berth⁃Jones J, et al. Intermittent short courses of cyclosporine microemulsion for the long⁃term management of psoriasis: a 2⁃year cohort study[J]. J Am Acad Dermatol, 2001,44(4):643⁃651. doi: 10.1067/mjd.2001.112400.
|
[22] |
Lebwohl M, Ellis C, Gottlieb A, et al. Cyclosporine consensus conference: with emphasis on the treatment of psoriasis[J]. J Am Acad Dermatol, 1998,39(3):464⁃475.
|
[23] |
Griffiths CE, Clark CM, Chalmers RJ, et al. A systematic review of treatments for severe psoriasis[J]. Health Technol Assess, 2000,4(40):1⁃125.
|
[24] |
Colombo D, Cassano N, Altomare G, et al. Psoriasis relapse evaluation with week⁃end cyclosporine A treatment: results of a randomized, double⁃blind, multicenter study[J]. Int J Immunopathol Pharmacol, 2010,23(4):1143⁃1152. doi: 10.1177/039463201002300418.
|
[25] |
Amor KT, Ryan C, Menter A. The use of cyclosporine in dermatology: part I[J]. J Am Acad Dermatol, 2010,63(6):925⁃946; quiz 947⁃948. doi: 10.1016/j.jaad.2010.02.063.
|
[26] |
Pathirana D, Ormerod AD, Saiag P, et al. European S3⁃guidelines on the systemic treatment of psoriasis vulgaris[J]. J Eur Acad Dermatol Venereol, 2009,23 Suppl 2:1⁃70. doi: 10.1111/j.1468⁃3083.2009.03389.x.
|
[27] |
Gollnick HP. Oral retinoids⁃⁃efficacy and toxicity in psoriasis[J]. Br J Dermatol, 1996,135 Suppl 49:6⁃17.
|
[28] |
Ling MR. Acitretin: optimal dosing strategies[J]. J Am Acad Dermatol, 1999,41(3 Pt 2):S13⁃S17.
|
[29] |
Carretero G, Ribera M, Belinchón I, et al. Guidelines for the use of acitretin in psoriasis. Psoriasis Group of the Spanish Academy of Dermatology and Venereology[J]. Actas Dermosifiliogr, 2013,104(7):598⁃616. doi: 10.1016/j.adengl.2013.01.001.
|
[30] |
Nast A, Gisondi P, Ormerod AD, et al. European S3⁃Guidelines on the systemic treatment of psoriasis vulgaris⁃⁃Update 2015⁃⁃Short version⁃⁃EDF in cooperation with EADV and IPC[J]. J Eur Acad Dermatol Venereol, 2015,29(12):2277⁃2294. doi: 10.1111/jdv.13354.
|
[31] |
Paller AS, Siegfried EC, Pariser DM, et al. Long⁃term safety and efficacy of etanercept in children and adolescents with plaque psoriasis[J]. J Am Acad Dermatol, 2016,74(2):280⁃287. e1⁃e3. doi: 10.1016/j.jaad.2015.09.056.
|
[32] |
Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate⁃to⁃severe psoriasis: a phase III, multicentre, double⁃blind trial[J]. Lancet, 2005,366(9494):1367⁃1374. doi: 10.1016/S0140⁃6736(05)67566⁃6.
|
[33] |
Menter A, Feldman SR, Weinstein GD, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate⁃to⁃severe plaque psoriasis[J]. J Am Acad Dermatol, 2007,56(1):31. e1⁃e15. doi: 10.1016/j.jaad.2006.07.017.
|
[34] |
Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial[J]. J Am Acad Dermatol, 2008,58(1):106⁃115. doi: 10. 1016/j.jaad.2007.09.010.
|
[35] |
Gordon K, Papp K, Poulin Y, et al. Long⁃term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open⁃label extension study for patients from REVEAL[J]. J Am Acad Dermatol, 2012,66(2):241⁃251. doi: 10.1016/j.jaad.2010.12.005.
|
[36] |
Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin⁃12/23 monoclonal antibody, in patients with psoriasis: 76⁃week results from a randomised, double⁃blind, placebo⁃controlled trial (PHOENIX 1)[J]. Lancet, 2008,371(9625):1665⁃1674. doi: 10.1016/S0140⁃6736(08)60725⁃4.
|
[37] |
Papp KA, Griffiths CE, Gordon K, et al. Long⁃term safety of ustekinumab in patients with moderate⁃to⁃severe psoriasis: final results from 5 years of follow⁃up[J]. Br J Dermatol, 2013,168(4):844⁃854. doi: 10.1111/bjd.12214.
|
[38] |
Thaçi D, Blauvelt A, Reich K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial[J]. J Am Acad Dermatol, 2015,73(3):400⁃409. doi: 10.1016/j.jaad. 2015.05.013.
|
[39] |
Lesner K, Reich A, Szepietowski JC, et al. Determinants of psychosocial health in psoriatic patients: a multi⁃national study[J]. Acta Derm Venereol, 2017,97(10):1182⁃1188. doi: 10. 2340/00015555⁃2760.
|